Observational studyInternational journal of clinical oncology2026
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.
Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI.
methodsOverall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics® Plus claims database (Jan 1, 2013, to Aug 31, 2021).
resultsOverall, 2L ARPI (n = 473) vs. taxane (n = 214) was associated with longer median OS (15.4 vs. 13.6 months). Patients receiving > 8 (n = 48) vs. ≤ 8 taxane cycles (n = 166) had longer median OS (18.4 vs. 11.9 months; p = 0.006). Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).
conclusionPatients who received > 8 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.